Literature DB >> 17978486

Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes.

So Hui Kim1, Eun-Jung Shin, Eun-Do Kim, Tsenguun Bayaraa, Susan Cooke Frost, Chang-Kee Hyun.   

Abstract

It has recently been known that berberine, an alkaloid of medicinal plants, has anti-hyperglycemic effects. To explore the mechanism underlying this effect, we used 3T3-L1 adipocytes for analyzing the signaling pathways that contribute to glucose transport. Treatment of berberine to 3T3-L1 adipocytes for 6 h enhanced basal glucose uptake both in normal and in insulin-resistant state, but the insulin-stimulated glucose uptake was not augmented significantly. Inhibition of phosphatidylinositol 3-kinase (PI 3-K) by wortmannin did not affect the berberine effect on basal glucose uptake. Berberine did not augment tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate (IRS)-1. Further, berberine had no effect on the activity of the insulin-sensitive downstream kinase, atypical protein kinase C (PKCzeta/lambda). However, interestingly, extracellular signal-regulated kinases (ERKs), which have been known to be responsible for the expression of glucose transporter (GLUT)1, were significantly activated in berberine-treated 3T3-L1 cells. As expected, the level of GLUT1 protein was increased both in normal and insulin-resistant cells in response to berberine. But berberine affected the expression of GLUT4 neither in normal nor in insulin-resistant cells. In addition, berberine treatment increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 cells, which has been reported to be associated with GLUT1-mediated glucose uptake. Together, we concluded that berberine increases glucose transport activity of 3T3-L1 adipocytes by enhancing GLUT1 expression and also stimulates the GLUT1-mediated glucose uptake by activating GLUT1, a result of AMPK stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978486     DOI: 10.1248/bpb.30.2120

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  39 in total

1.  Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach.

Authors:  Zhen-zhong Yang; Wei Liu; Feng Zhang; Zheng Li; Yi-yu Cheng
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

2.  Berberine activates bitter taste responses of enteroendocrine STC-1 cells.

Authors:  Xiao Yue; Jie Liang; Fu Gu; Dongshu Du; Fuxue Chen
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

3.  Alkaline pH activates the transport activity of GLUT1 in L929 fibroblast cells.

Authors:  Stephen M Gunnink; Samuel A Kerk; Benjamin D Kuiper; Ola D Alabi; David P Kuipers; Riemer C Praamsma; Kathryn E Wrobel; Larry L Louters
Journal:  Biochimie       Date:  2013-12-12       Impact factor: 4.079

4.  Adipose-specific deletion of stearoyl-CoA desaturase 1 up-regulates the glucose transporter GLUT1 in adipose tissue.

Authors:  Chang-Kee Hyun; Eun-Do Kim; Matthew T Flowers; Xueqing Liu; Eunha Kim; Maggie Strable; James M Ntambi
Journal:  Biochem Biophys Res Commun       Date:  2010-07-22       Impact factor: 3.575

5.  Cardiovascular and metabolic effects of Berberine.

Authors:  Flora Affuso; Valentina Mercurio; Valeria Fazio; Serafino Fazio
Journal:  World J Cardiol       Date:  2010-04-26

6.  Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes.

Authors:  Tianjiong Lou; Zhongai Zhang; Zhilei Xi; Kang Liu; Lin Li; Baolin Liu; Fang Huang
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

7.  Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism.

Authors:  Qian Zhang; Xinhua Xiao; Kai Feng; Tong Wang; Wenhui Li; Tao Yuan; Xiaofang Sun; Qi Sun; Hongding Xiang; Heng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-26       Impact factor: 2.629

8.  Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction.

Authors:  Rajesh Kumar Suman; Manjusha K Borde; Ipseeta Ray Mohanty; Ujwala Maheshwari; Y A Deshmukh
Journal:  J Clin Diagn Res       Date:  2016-03-01

9.  Differential regulation of GLUT1 activity in human corneal limbal epithelial cells and fibroblasts.

Authors:  David P Kuipers; Jared P Scripture; Stephen M Gunnink; Matthew J Salie; Mark P Schotanus; John L Ubels; Larry L Louters
Journal:  Biochimie       Date:  2012-09-23       Impact factor: 4.079

Review 10.  Traditional chinese medicine in treatment of metabolic syndrome.

Authors:  Jun Yin; Hanjie Zhang; Jianping Ye
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.